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ABSTRACT 
Soluble-Mesothelin Related Peptide (SMRP) is a promising diagnostic biomarker for 
malignant pleural mesothelioma (MPM), but various confounders hamper its usefulness in 
surveillance programs. We previously showed that a single nucleotide polymorphism (SNP) 
within the 3’untranslated region (3’UTR) of mesothelin (MSLN) gene could affect the levels 
of SMRP. Here, we focused on SNPs located within MSLN promoter and found a strong 
association between serum SMRP and variant alleles of rs3764247, rs3764246 (that is in 
strong linkage disequilibrium with rs2235504), and rs2235503 in non-MPM subjects. The 
inclusion of the genotype information led to an increase in SMRP specificity from 79.9% to 
85.5%. Although not statistically significant, the MPM population showed the same trend of 
association. In order to study the biological role of these SNPs, the promoter region of MSLN 
was cloned upstream a reporter gene and the four most common haplotypes were compared 
in a dual luciferase assay. Rs3764247 was shown to have a functional role itself. The other 
SNPs were shown to interact with each other in a more complex way. Altogether, these data 
support the idea that SMRP performance is affected by individual (i.e. genetic) variables and 
that MSLN expression is influenced by SNPs located within the promoter regulatory region.  
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INTRODUCTION 
Mesothelin (MSLN) is a membrane-bound glycoprotein physiologically expressed by the 
mesothelial tissues of pleura, peritoneum, and pericardium (Hassan et al., 2004). Although its 
biological function is still unknown (Bera and Pastan, 2000), many types of cancer, including 
malignant pleural mesothelioma (MPM), show increased expression of MSLN compared to 
their non-malignant counterparts (Hassan and Ho, 2008). MPM is a highly aggressive tumor 
of the pleural cavities, associated with asbestos exposure and characterized by challenging 
diagnosis and poor prognosis (Panou et al., 2015). In recent years, several research groups 
suggested that MSLN could be helpful in the management of MPM, both as diagnostic tool 
(Robinson et al., 2003; Cristaudo et., 2007) and putative therapeutic target (Hassan et al., 
2010; Hassan et al., 2014). In particular, high levels of the soluble form of MSLN, the so-
called SMRP (Soluble Mesothelin-Related Peptides), were repeatedly observed in serum 
samples of MPM patients when compared to various types of control groups (Cristaudo et al., 
2007; Pass et al., 2008; Fukuoka et a., 2013). Nonetheless, in spite of the initial findings, the 
real usefulness of SMRP within surveillance programs is hampered by a relatively high rate 
of false negatives as well as false positives (Cui et al., 2014). Various demographic and 
clinical variables were reported as possible confounders, such as body mass index, age, 
glomerular filtration rate, and lung function (Hollevoet et al., 2009; Park et al., 2010; Filiberti 
et al., 2013). Genetic factors were also shown to affect SMRP levels in non-MPM subjects. 
Thus, the inclusion of individuals’ genetic information could improve the ROC curves 
calculation leading to slight improvements of the performance of SMRP as biomarker 
(Garritano et al., 2014). Previously, studying a broad cohort of non-MPM subjects, we 
reported an association between serum SMRP levels and rs1057147, a single nucleotide 
polymorphism (SNP) located within the 3’untranslated region (3’UTR) of MSLN. This SNP 
lies within the binding site for miR-611, thereby affecting the post-transcriptional regulation 
of MSLN mRNA (Garritano et al., 2014). Similarly, genetic variants located within the 
promoter region of MSLN were found to be associated with SMRP levels in a small group of 
non-MPM volunteers (Cristaudo et al., 2011). Healthy subjects carrying the variant allele of 
rs3764247 A>C (reported as New1 in the original publication) showed increased SMRP 
levels compared to those carrying the AA genotype (Cristaudo et al., 2011). This could be 
ascribed to a different regulatory pattern depending on the presence of the variant or common 
allele. In the present work we analysed a large sample set and we were able to replicate the 
association between rs3764247 and SMRP levels. Moreover, in order to further explore the 
role of genetic variants in MSLN/SMRP regulation, we (i) evaluated the association between 
SMRP and other SNPs located within the proximal MSLN promoter and (ii) performed an in 
vitro study to assess the biological role of the selected SNPs. Altogether, these findings could 
help to refine the use of SMRP as diagnostic biomarker and to shed some light in the 
regulatory mechanisms of MSLN gene.  
MATERIALS AND METHODS 
SNPs selection 
In the pilot study, an association between rs3764247 and SMRP was found (Cristaudo et al., 
2011). Here, the association analysis was extended to other SNPs lying within the region of 
the proximal promoter of MSLN. Thus, selection criteria for the SNPs were: (i) to lie within 
1000 bp (arbitrarily chosen) upstream the MSLN transcriptional start site (TSS); (ii) the 
frequency of the rare allele must be >0.05; (iii) to be reported as associated with MSLN 
mRNA expression in 278 lung tissue samples according to GTex portal 
(http://www.gtexportal.org/home/; Lonsdale et al., 2013). The linkage disequilibrium (LD) 
between the selected SNPs (i.e. rs3764247 A>C, rs3764246 A>G, rs2235503 C>A, 
rs2235504 A>G) and the most common haplotypes was estimated with HaploView software 
version 4.2 (https://www.broadinstitute.org/.../haploview/haploview) using the TSI (Tuscans 
in Italy) population (however, CEU samples gave overlapping results).  
Population description and genotyping 
A total of 689 non-MPM subjects (healthy individuals n=371, or patients affected by benign 
respiratory diseases, BRDs, n=318) and 70 MPM volunteers were recruited at the University 
Hospital of Pisa as part of an occupational surveillance program on workers previously 
exposed to asbestos, as described in detail in Garritano et al., 2014. Table 1 shows the clinical 
and demographic characteristics of the sample set. The study was approved by the 
institutional ethical committee of the University Hospital of Pisa. All subjects gave written 
informed consent. For genotyping, whole blood and serum samples were obtained by 
venipuncture and kept at -80°C until examination. DNA was extracted from whole blood 
samples using EuroGOLD Blood DNA Mini Kit (EuroClone, Pero, Italy). Genotyping of the 
three selected SNPs (i.e. rs3764247, rs3764246 and rs2235503) was performed using 
KASPar® PCR SNP genotyping system (LGC Genomics Ltd, Teddington, Middlesex, UK) 
with a success rate >96%. Allele frequencies (shown in Table 1) were in agreement with 
those reported in HapMap project for TSI (0.20, 0.25, and 0.15 for rs3764247, rs3764246 and 
rs2235503, respectively) and followed the Hardy-Weinberg equilibrium (P=0.753, P=0.583, 
and P=0.625, respectively). Serum SMRP levels were measured using an enzyme-linked 
immuno-sorbent assay according to the manufacturer’s instructions (Mesomark, Fujirebio 
Diagnostics, Japan).  
Association analyses between genotypes and SMRP levels 
In order to verify the association between genotypes and serum SMRP levels, one-way 
analysis of variance (ANOVA) was performed, stratified for health status (healthy, BRD, 
MPM), for each SNP. Tukey’s multiple comparison tests were performed to assess pairwise 
differences between the three genotypes within each group. In order to ascertain the global 
role of these SNPs in the association with SMRP in the different diagnostic groups, both the 
“non-MPM” (healthy subjects + BRD patients) and the MPM groups were stratified 
according to a three-SNPs classifier. According to this classifier, individuals carrying the 
common homozygote genotype for all the SNPs were considered as the reference category 
and were referred as carriers of the “L genotype” (L=low expression), whereas all the 
remaining subjects (i.e. carriers of at least one variant allele in one of the three SNPs) were 
considered to carry the “H genotype” (H=high). Then, a multivariate analysis of variance 
(mANOVA) was carried out to assess the association between SMRP values and L/H 
genotypes for each diagnostic group. The statistical significance threshold was set at 0.05 for 
all the analyses, which were performed using and StatGraphics Centurion XVI software 
(Manugistic, CA, USA). 
Receiver Operating Characteristic (ROC) curves were generated with MedCalc statistical 
software (version 12.7.2.0, MedCalc Software, Belgium) comparing the non-MPM group 
versus the MPM group. First, the ROC curves were calculated without taking into account the 
genotypes. Then the curves were recalculated using SMRP levels of alternatively non-MPM 
volunteers carrying L or H genotype, versus the whole group of MPM patients (this group 
was not split in H/L genotype because no statistically significant differences were found in 
MPM patients). 
Plasmids construction 
The putative human MSLN promoter from nucleotides -1 to -1073 relative to the transcription 
start site was amplified by Q5® High-Fidelity DNA Polymerase (NEB, Ipswich, USA). As 
template, an individual carrying the common homozygote genotype for all the SNPs in study 
was selected from our sample set. The resultant polymerase chain reaction (PCR) amplicon 
was subsequently cloned into the XhoI site of the pGL3-basic vector (Promega, Madison, 
WI) using CloneEZ® PCR Cloning Kit (GenScript, Piscataway, USA). This construct, 
bearing the most common haplotype in the TSI population, is from now on referred as 
“pGL3_HAP1”. Subsequent site-directed mutagenesis reactions were performed to generate 
the other haplotype-mimicking plasmids with QuikChange II Site-Directed Mutagenesis Kits 
(Agilent, Santa Clara, CA, USA). The fidelity of the resulting constructs (pGL3_HAP1/2/3/4) 
was confirmed by sequencing, using the pGL3 external primers (pGL3_F and pGL3_R). The 
sequence of cloning, mutagenesis, and sequencing primers are reported in Supplementary 
Table 1.  
Cell culture and luciferase reporter assays 
Non-malignant transformed human pleural mesothelial cells (Met-5A) (Ke et al., 1989) were 
purchased from ATTC (American Type Tissue Collection) and cultured in Medium 199 
(Gibco in Life Technologies) supplemented with 10% FBS, 1% pen/strep, 3 nM epidermal 
growth factor, 400 nM hydrocortisone, and 870 nM insulin. Met-5A cells were maintained in 
a humidified incubator at 37°C in 5% CO2. 
In three independent experiments, Met-5A cells were seeded in 24-wells plates at a final 
density of 50,000 cells/well and incubated for 24 hours. Cells were then transfected at 60-
80% confluence with 400 ng of pGL3_HAP1/2/3/4 and 10 ng of internal control vector pRL-
SV40 (Promega, Madison, USA) using Attractene reagent (Qiagen, Hilden, Germany). 
Twenty-four hours after transfection, a Dual-Luciferase Reporter Assay (Promega) was 
performed. Relative luciferase units (RLU) were expressed as mean value of the firefly 
luciferase/Renilla luciferase ratio of three independent experiments. 
Functional annotation of the SNPs of interest 
To assess the possible functional role of the SNPs of interest, we used the ENCODE-based 
tool HaploReg v4 (www.broadinstitute.org/mammals/haploreg) and RegulomeDB 
(http://www.regulomedb.org/). Overall, SNPs were analysed for mapping within DNase I 
hypersensitive sites (DHSs), regulatory elements (enhancers and promoters), regulatory 
protein binding sites and altered motifs of transcription factors.  
RESULTS 
SNPs selection 
In order to identify the genetic variants within MSLN proximal promoter (~1000 bp upstream 
to TSS) to be studied in association with SMRP, we searched for all SNPs significantly 
associated with MSLN mRNA expression in lung tissues on GTex portal (pleural tissues were 
unavailable). We found 86 cis-eQTLs with P-values ranging from 4.9x10-6 to 4.4x10-33. The 
region spanning MSLN TSS shows the highest associated SNPs. Table 2 lists the top ten 
associated SNPs with their main features. Among the 86 associated SNPs, we selected those 
lying within the 1000 bp upstream to TSS, i.e. rs3764247 (16:g.810039 A>C), rs3764246 
(16:g.810143 A>G), rs2235503 (16:g.810593 C>A), rs2235504 (16:g.810655 A>G). Since a 
strong LD (r2=0.94) was present between rs3764246 and rs2235504, we chose rs3764247, 
rs3764246 and rs2235503 for the genotyping analyses in association with SMRP. 
Genotyping results in association with SMRP levels in healthy, BRD, and MPM subjects 
As expected, the group of MPM patients showed a mean level of serum SMRP of 3.58 nM 
(±0.49, standard error of the mean SEM), significantly elevated (ANOVA, P<0.0001) when 
compared to the groups of healthy (0.94±0.03) or BRD (1.04±0.03) subjects. When the 
SMRP levels were analyzed in relation to genotypes for each SNP separately, a significant 
association (overall P-values calculated with ANOVA <0.0001) was found between SMRP 
and all the SNPs in the non-MPM category (healthy and BRD subjects). As it can be seen in 
Table 3 and in Figure 1, for each SNP there is an increasing and statistically significant trend 
of SMRP levels in relation to the carried number of variant alleles. This trend was observed 
among healthy individuals as well as for BRD subjects, although the comparison between 
heterozygotes and variant homozygotes was not significant for rs3764247 and rs2235503 in 
the latter group. Interestingly, similar trends were also observed in the group of MPM 
patients, however no statistically significant differences were achieved for any of the SNPs (P 
= 0.166, 0.363 and 0.373 for rs3764247, rs3764246, and rs2235503, respectively).  
In order to ascertain the global role of these SNPs, we used the three-SNPs classifier 
assigning the H or L genotype for each volunteer of this study. Then, a mANOVA was 
employed with “health status” and “classifier” as independent factors and this model 
confirmed that SMRP levels were associated with the promoter genotype (L vs H, P=0.001) 
and diagnosis (non-MPM vs MPM P <0.0001). Moreover, the interaction between these 
factors was not statistically significant (P=0.3730), given that also among MPM patients the 
group carrying the L genotype showed an average SMRP lower than the patients carrying the 
H genotype (however, the difference between H and L genotype within MPM patients was 
not statistically significant). 
When SMRP was evaluated as a biomarker regardless of the genotype information, the ROC 
curves showed an AUC of 0.867 (95% CI = 0.841-0.890). The Youden’s J index (0.566) 
pointed at the SMRP cut-off value of 1.28 nM, resulting in a sensitivity of 76.7% and a 
specificity of 79.9%. At a cut-off value of 1 nM (as suggested in previous works (Cristaudo et 
al., 2011; Cristaudo et al., 2010)), the sensitivity rose to 87.7%, but the specificity dropped to 
64.1%. When considering the genotypes, non-MPM subjects were stratified by L or H 
promoter status. On the other hand, MPM patients were considered as a whole. In fact, their 
SMRP levels did not associate with genotypes in a statistically significant way and their 
stratification could have led to a reduction of the statistical power of the analysis. In 
Supplementary Figure 1 the distributions of SMRP values of MPM patients and controls with 
either H- or L-promoter are reported. In the ROC curves, the lowest rates of false positives 
were obtained among non-MPM subjects carrying the L-promoter, where Youden’s J index 
rose to 0.690 (at 1.11 nM), the AUC to 0.922, and the sensitivity and specificity to 83.6% and 
85.5%, respectively. ROC curves calculated for non-MPM individuals with H-promoter 
showed a worse performance of SMRP, with AUC of 0.801 and a decrease of specificity to 
67% in correspondence of Youden’s J index (1.28 nM). Figure 2 A-B-C reports the discussed 
ROC curves, whereas Table 4 reports the punctual values of sensitivities and specificities for 
each group. The different cut-off values with their corresponding sensitivity and specificity 
for L and H groups are reported in Supplementary Table 2 and 3, for brevity. 
In vitro study on the SNPs located within the MSLN promoter reported a functional role 
for rs3764247 
In order to elucidate the biological role of the SNPs found to be associated with SMRP, an in 
vitro study was performed cloning the putative promoter region of MSLN upstream to a 
reporter gene. We then applied site-directed mutagenesis to obtain the most common 
haplotypes present in the population (i.e. pGL3_HAP1 A-A-C-A; pGL3_HAP2 C-G-A-G; 
pGL3_HAP3 A-G-C-G; pGL3_HAP4 C-A-C-A). Since the strongest association between 
genotype and SMRP was found among non-MPM individuals, we employed Met-5A cells as 
a model of non-MPM tissue. The vectors were transfected into these cells and the reporter 
activity under the control of promoters bearing different genetics variants was evaluated. A 
significant difference in RLU (overall P-value calculated with ANOVA <0.0001) was found 
among the constructs. When compared to pGL3_HAP1 (artificially set at 100%, ± 4% SEM), 
RLU values of pGL3_HAP2, pGL3_HAP3 and pGL3_HAP4 were 121% (±8%), 97% 
(±12%) and 182% (±18%), respectively. The pairwise comparisons revealed that the 
difference between pGL3_HAP1 and pGL3_HAP4 was statistically significant, as shown in 
Figure 3, whereas that between pGL3_HAP1 and pGL3_HAP2 is close to the statistical 
significance (P=0.064).   
Functional annotation of the SNPs of interest 
According to luciferase assay results, rs3764247 seemed to play a direct role in the regulation 
of the MSLN gene. HaploReg v4 showed that this SNP is located in DNase I hypersensitive 
sites (DHSs) in neuronal progenitors and astrocyte primary cells. According to RegulomeDB, 
it lies within enhancer regions in lung tissues and it is suggested to affect binding sites for 
two transcription factors, namely Staf and ZNF143. As pGL3_HAP3 did not show any 
difference in luciferase activity when compared to pGL3_HAP1, we could conclude that 
rs3764246 and rs2235504 did not exert a direct functional role in the regulation of MSLN. 
Nonetheless, rs2235505, located in the second intron of the MSLN gene, shows a very high 
LD with these SNPs (r2>0.9). Thus, we analyzed the functional annotation available about 
rs2235505 in HaploReg and RegulomeDB database. It was reported to be located in DHSs in 
HeLa and HepG2 cell lines and to affect several transcription factor binding motifs such as 
BHLHE40, CTCF, PLAG1 and Rad21. It was also shown to bind RCOR1 chromatin binding 
protein in HeLa cells. No alteration in the splicing mechanism was predicted by SpliceAid 
software. A visual summary of the results of the functional study on the MSLN promoter is 
reported in Figure 4.   
DISCUSSION 
MSLN is a membrane glycoprotein described as functionally involved in many malignancies, 
including MPM. It has been repeatedly reported that the measurement of the levels of its 
soluble form (SMRP) could help to discriminate the MPM from the non-MPM subjects, 
although its performance is limited by high rates of false positives and false negatives (Cui et 
al., 2014). Regulatory SNPs within promoters play an important role in various diseases, 
including cancer (Saeed et al., 2013;  Wu et al., 2014; Cingeetham et al., 2015), myocardial 
infarction (Domingues-Montanari et al., 2008) and diabetes (Singh et al., 2013). In the 
present study, we were aimed to broaden the knowledge about the biological role played by 
genetic variants located within MSLN promoter region with potential impact also on the 
performance of SMRP as diagnostic biomarker. Thus, we selected four SNPs (rs3764247 
A>C, rs3764246 A>G, rs2235503 C>A, rs2235504 A>G) within 1000 bp upstream the 
MSLN TSS and, in the first part of the study, we investigated the association between SMRP 
and genetic variants in over 700 individuals, awarding reliability against possible chance 
findings. We found associations between genotypes and SMRP levels among non-MPM 
individuals, in agreement with those reported in the cis-eQTL database within GTex portal. 
The genotype, together with other confounders (Park et al., 2010; Filiberti et al., 2013), 
contributes to the wide inter-individual variations commonly found in serum SMRP levels 
(Cui et al., 2014). Considering the global effect of these SNPs (summarized in the L/H 
classifier), different sensitivities and specificities were found when SMRP was employed as a 
biomarker. The inclusion of the genotype in the calculation of ROC curves led to an 
improved diagnostic performance, with the lowest rate of false positives in individuals 
carrying the L genotype, implying that high levels of SMRP could be more alarming for 
people carrying this genotype. In the second part of the study, we found that the genotype-
dependent levels of SMRP paralleled, at least partially, the results obtained in vitro in non-
MPM Met-5A cells, where the functional role of naturally occurring haplotypes was 
evaluated. Typically, the functional study of SNPs within promoters is very challenging, 
especially when haplotypes are studied. Since reporter vectors focus on a narrow window of 
the genome and SNPs could interact with each other in a complex way, the behavior of 
haplotype-bearing constructs is not easy to interpret, as suggested by several previous works 
(Terry et al., 2000; Bellini et al., 2010; Zhao et al., 2015; Shin et al., 2015). Thus, differences 
among haplotypes are not easily interpretable, such as those occurring between pGL3_HAP2 
and pGL3_HAP4 in the present study. However, a direct effect of rs3764247 was suggested 
by the higher expression of pGL3_HAP4 when compared to pGL3_HAP1, and further 
studies are needed in order to ascertain its role in MSLN regulation. For instance, it is 
reported to affect the binding sites of transcription factors such as Staf or ZNF143, thus future 
research could be directed towards the experimental validation of this interaction in 
mesothelial cells. Moreover, according to the luciferase assay, rs3764246 and rs2235504 are 
unlikely to play a direct role in MSLN regulation, as suggested by the similar expression of 
pGL3_HAP3 and pGL3_HAP1. However, rs2235505, which is located within intron 2 of 
MSLN, is in strong LD with them and it could be responsible for the differential levels of 
SMRP found in our association study. This SNP is also included in the list of associated 
SNPs in cis-eQTL database and functional annotations reported several transcription factor-
binding sites affected by its variant allele. Thus, rs2235505 could be worth of further 
investigations including an in vitro functional study with a similar approach to the one 
performed here. Interestingly, our results are reminiscent of previous observations concerning 
SNPs lying within the PSA (prostate-specific antigen) gene promoter (Cramer et al., 2008). In 
fact, these SNPs were shown to contribute to individual differences among healthy men in the 
levels of serum PSA, a common biomarker for prostate cancer (Cramer et al., 2008). This 
reinforces the notion of implementing the genetic information when considering specific 
biomarkers in surveillance programs. Interestingly, we noticed that, similarly to what 
observed in non-MPM volunteers, among MPM patients rare homozygotes had the highest 
average levels of SMRP, whereas heterozygotes showed intermediate levels. However, these 
trends, as well as the difference between H and L genotypes, were not statistically significant. 
We hypothesize that the lack of statistical significance has to be ascribed to the relative small 
number of MPM patients recruited in this study. We could not collect more patients, being 
MPM a rare disease, however it is likely that also among patients the increase of SMRP could 
be more evident among carriers of the H genotype.  
In conclusion, we reported that SMRP levels are affected by genetic variants, with the 
consequence of suggesting different “warning” thresholds for healthy subjects carrying 
different genotypes. A challenging aspect of the biomarker study would be the identification 
of SNPs explaining the presence of false negative results, i.e. low SMRP levels among MPM 
patients. The recruitment of a larger sample set of MPM individuals should be required for 
this purpose. In the present work, a functional role for some of these SNPs was suggested and 
needs further investigation. These analyses could help in understanding the biological 
mechanisms of transcriptional regulation of MSLN gene and eventually contribute to 
explaining the high levels of this protein in MPM, shedding some lights also in the 
mechanisms of pleural carcinogenesis. 
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FIGURE LEGENDS 
Figure 1. Association between genetic variants within the MSLN promoter (i.e. rs3764247, 
rs3764246 and rs2235503) and SMRP levels in healthy (A), BRD (B) and MPM (C) subjects. 
Asterisks show a statistical significance (P < 0.05) in the Tukey’s test for pairwise differences 
within the ANOVA model. The columns represent mean values, the bars show standard error 
of the mean (SEM). 
Figure 2. ROC curves obtained with MedCalc software comparing (A) the whole non-MPM 
group vs MPM; (B) L genotype group (non-MPM subjects carrying common homozygote 
genotype for all the SNPs) vs MPM; (C) H genotype group (all the other non-MPM 
individuals) vs MPM. AUC, sensitivities, specificities and cut-off value (“criterion”) at the 
Youden’s J index are shown in the figure. 
Figure 3. Luciferase assay results on Met-5A cells when the four haplotypes-mimicking 
plasmids were co-transfected with pRL-SV40 control vector. RLU obtained with 
pGL3_HAP1 transfection is reported as 100% and used as reference for statistical evaluation. 
The columns represent mean values, the bars show standard error of the mean (SEM). 
Figure 4. Summary of the results of the functional study on the MSLN promoter. The grey 
square represents the cloned region of about 1000 bp with the SNPs having a MAF>0.05. The 
transcription factors binding to the polymorphic sites and affected by these SNPs (according 
to HaploReg and/or Regulome DB) are also reported. The plot linking the SNPs each other 
shows the r2 values of LD as a greyscale (plotted with Haploview). The four most common 
haplotypes and their corresponding differences in luciferase activity are shown in the lower 
part of the figure, where a qualitative trend of RLU is reported for each haplotype-mimicking 
plasmid, referred to HAP_1 as reference.      
